Drug Industry Group Starts Ad Campaign to Defend Pricing

  • Biotech lobby spends millions to say new treatments save lives
  • Group distances itself from price-hiking Valeant, Turing

A top pharmaceutical lobbying group is launching an ad campaign to defend drugmakers that have been under fire for their pricing practices.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.